Anbio Biotechnology - Class A Ordinary Shares (NNNN)
Competitors to Anbio Biotechnology - Class A Ordinary Shares (NNNN)
Amgen Inc. AMGN -1.40%
Amgen is a leading biotechnology company that competes with Anbio Biotechnology primarily through its extensive pipeline of innovative therapies and established position in the market. Amgen has a strong portfolio of biologic medications, which offers them a competitive edge in terms of experience, regulatory approvals, and a robust sales infrastructure. In contrast, Anbio focuses on developing novel therapies; however, it lacks the same breadth of products and market presence as Amgen. This larger scale and brand power give Amgen a competitive advantage.
Biogen Inc. BIIB +1.11%
Biogen focuses on neurological disorders, an area that somewhat overlaps with Anbio Biotechnology's interests. While Biogen has a strong portfolio of treatments and a robust pipeline, Anbio is looking to innovate within similar therapeutic areas. However, Biogen's longstanding reputation, extensive clinical trial experience, and successful market presence provide it with a competitive edge over Anbio, which is still establishing itself in the sector.
Gilead Sciences, Inc. GILD -0.56%
Gilead Sciences competes against Anbio Biotechnology through its strong focus on antiviral therapies, particularly in the treatment of HIV and viral hepatitis. Gilead’s extensive experience in drug development, coupled with a vast commercial network, allows them to dominate in specific therapeutic areas where Anbio is also attempting to establish a foothold. Gilead's established products and revenues give them a significant competitive advantage over newer entrants like Anbio.
Novartis AG NVS -0.01%
Novartis is a multinational pharmaceutical company that competes with Anbio Biotechnology in a variety of therapeutic domains including oncology and gene therapy. Novartis’s scale, broad product range, and established processes for drug development and commercialization provide a significant advantage. While Anbio seeks to innovate and develop unique therapies, it lacks the comprehensive market access and resources that Novartis enjoys, making the latter a formidable competitor.
Regeneron Pharmaceuticals REGN +0.28%
Regeneron Pharmaceuticals competes with Anbio Biotechnology in the field of biopharmaceuticals, particularly in areas such as monoclonal antibody development and genetic medicine. Regeneron's established track record in bringing successful products to market, as well as their investment in research and development, allows them to maintain a leadership position. While Anbio aims to carve out its niche with innovative drugs, Regeneron's substantial financial resources and market acceptability provide them with a competitive advantage.